Canada Markets closed

Mesoblast Limited (MEOBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.85890.0000 (0.00%)
At close: 11:05AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8589
Open0.8589
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.8589 - 0.8589
52 Week Range0.8000 - 1.7400
Volume550,000
Avg. Volume10,321
Market Cap556.019M
Beta (5Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.1560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Simply Wall St.

    What Type Of Shareholders Make Up Mesoblast Limited's (ASX:MSB) Share Registry?

    The big shareholder groups in Mesoblast Limited ( ASX:MSB ) have power over the company. Institutions will often hold...

  • GlobeNewswire

    Appendix 4C Quarterly Activity Report

    Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ

  • Zacks

    BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study

    BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.